Clementine Karageorgiou | PubMed Health

PubMed2006

Working-delayed memory difference detects mild cognitive impairment without being affected by age and education.

Performance on neuropsychological tests is affected by age and education, which makes the early detection of cognitive impairment difficult when assessing individuals of varying levels of education. We examined the effects of age, education, and gender on three memory indexes of the Wechsler Memory Scale-III, Delayed Memory, Working Memory and the difference between Working-Delayed Memory in a sample of patients with amnestic Mild Cognitive Impairment, patients with mild probable Alzheimer's disease, and a nondemented elderly comparison group. Whereas Delayed and Working Memory scores were affected by participant type, age, and education, the Working-Delayed Memory difference score was affected by participant type, only. Our preliminary conclusions, pending replication of the findings with a larger sample, are that working-delayed memory difference was sensitive to early memory decline without being affected by age and education.

Aged↗

PubMed2002

A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy.

This multicentre randomised double blind crossover trial tested the short term efficacy of intravenous immunoglobulin (IVIg) 2.0 g/kg given over 24 or 48 hours in patients with paraproteinaemic demyelinating neuropathy (PDN). Twenty-two patients were randomised and completed the trial. After 2 weeks, the overall disability grade decreased during both IVIg treatment and placebo but neither change was significant nor was the mean difference between the treatment effects. After 4 weeks the overall disability decreased by a mean of 0.55 [0.67] grades during the IVIg period (p = 0.001) while it was substantially unmodified during the placebo period. The mean difference between the treatment effects was significant (p = 0.05). Overall during the IVIg period 10 patients improved and 11 were stable and one got worse. During the placebo period 4 patients improved, 4 deteriorated and 14 were stable. Many secondary outcome measures, including Rankin scale, time to walk 10 metres, grip strength, sensory symptoms score were significantly better during IVIg treatment. Two serious adverse events occurred during the trial, both during placebo treatment. In conclusion the trial showed some short-term benefit of IVIg in about half of the patients confirming previous observation.

Aged↗